Format

Send to

Choose Destination
Br J Haematol. 2019 Apr 7. doi: 10.1111/bjh.15911. [Epub ahead of print]

Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia.

Author information

1
Department of Academic Haematology, UCL Cancer Institute, London, UK.
2
Katherine Dormandy Haemophilia & Thrombosis Centre, Royal Free Hospital, London, UK.

KEYWORDS:

ROR1; bispecific T cell engager; chronic lymphocytic leukaemia; ibrutinib; immunotherapy

PMID:
30957227
DOI:
10.1111/bjh.15911

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center